ArticleUrology2022

Complete Pathologic Response to Pembrolizumab and Axitinib in a Patient With Sarcomatoid RCC and Ocrelizumab-Treated Multiple Sclerosis.

Kevin Neuzil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.